Rafferty Asset Management
PRME icon

Rafferty Asset Management’s Prime Medicine PRME Stock Holding History

Rafferty Asset Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$750K Buy
215,582
+27,871
+15% +$106K ﹤0.01% 830
2025
Q4 		$651K Buy
+187,711
New +$835K ﹤0.01% 869
2023
Q4 		– Sell
-128,876
Closed -$1.23M – 1093
2023
Q3 		$1.23M Buy
+128,876
New +$1.67M 0.01% 738

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Rafferty Asset Management's PRME Position: Q1 2026 in Review

Rafferty Asset Management increased its Prime Medicine (PRME) stake by 15% in Q1 2026, buying an estimated $106K and bringing the position to 215,582 shares worth $750K. The position accounts for ﹤0.01% of the portfolio, ranked #830.

Rafferty Asset Management first reported a position in PRME in Q3 2023 and has held it in 3 quarters since. The position peaked at $1.23M in Q3 2023. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Rafferty Asset Management held 215,582 shares of Prime Medicine worth $750K as of Q1 2026.
  • Rafferty Asset Management bought 27,871 Prime Medicine shares in Q1 2026, an estimated $106K.
  • Prime Medicine made up ﹤0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #830 holding.
  • Rafferty Asset Management first reported a position in Prime Medicine in Q3 2023 and has held it in 3 quarters since.
  • Rafferty Asset Management's Prime Medicine position peaked at $1.23M in Q3 2023.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.